

Approved Antivirals: COVID-19, Influenza, Smallpox/Other Poxviruses*

Approved S.A. (n=14)

| | |
|------------------------|--------------------|
| Ensitrelvir (S-217622) | Molnupiravir |
| Nirmatrelvir/rtv | Remdesivir |
| Amantadine | Rimantadine |
| Favipiravir | Baloxavir Marboxil |
| Laninamivir | Oseltamivir |
| Peramivir | Zanamivir |
| Tecovirimat** | Brincidofovir** |

Approved O.N.A. (n=12)

| | |
|-----------------------|-----------------------|
| Azvudine | Umifenovir |
| Leritrelvir (RAY1216) | Simnotrelvir/rtv |
| Enisamium (VR17-04) | Triazavirin |
| Favipiravir | Mindeudesivir (VV116) |
| Triazavirin | Umifenovir |
| Enisamium (VR17-04) | NIOH-14** |

Indication

| | | |
|---------------|----------------|-------------------------------|
| COVID-19 (12) | Influenza (11) | Smallpox/Other Poxviruses (3) |
|---------------|----------------|-------------------------------|

** New; Change in Status

- 22 distinct antiviral compounds have received regulatory approval for COVID-19, Influenza, or Smallpox/Other Poxviruses
- 4 compounds are approved for COVID-19 and Influenza (favipiravir, triazavirin, umifenovir, and enisamium)
- 3 compounds have regulatory authorization by Animal Rule Development or similar mechanism
 - Tecovirimat is approved for Smallpox in U.S. & EU, and Cowpox and Mpox in EU only
 - Brincidofovir for Smallpox in U.S.
 - NIOH-14 for Smallpox in Russia

*As of July 12, 2024; WHO defined Other National Authority (<https://www.who.int/publications/m/item/list-of-transitional-wlas>)

Antiviral-Indication Expansions: Preclinical & Clinical Compound/Indications

Investigational: Antiviral compounds in clinical phase development for a different virus disease indication.

Approved: Antiviral compounds approved for treatment of a different virus disease indication.



- ▶ 6 of these antivirals (favipiravir, remdesivir, molnupiravir, amantadine, oseltamivir, & zanamivir) are approved for treatment of COVID-19 and/or Influenza.
 - ▶ Valganciclovir and cidofovir are approved for treating CMV disease.
- ▶ Favipiravir has the most indication expansions under evaluation (9) followed by remdesivir (6).

*As of July 12, 2024



INTREPID ALLIANCE

INTERNATIONAL READINESS FOR PREVENTING INFECTIOUS VIRAL DISEASE

**Interested
in engaging
with us?**

We welcome all feedback through [our online portal](#). As with previous listings, developers are invited to submit non-confidential information on their compound candidates. All reports are updated quarterly.

For more information, contact nina@intrepidalliance.org.

 intrepidalliance.org

 linkedin.com/company/intrepid-alliance